JP2018513862A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513862A5 JP2018513862A5 JP2017554426A JP2017554426A JP2018513862A5 JP 2018513862 A5 JP2018513862 A5 JP 2018513862A5 JP 2017554426 A JP2017554426 A JP 2017554426A JP 2017554426 A JP2017554426 A JP 2017554426A JP 2018513862 A5 JP2018513862 A5 JP 2018513862A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- sjogren
- ylamine
- quinolin
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 4
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000034943 Primary Sjögren syndrome Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506786.1A GB201506786D0 (en) | 2015-04-21 | 2015-04-21 | Therapeutic use |
| GB1506786.1 | 2015-04-21 | ||
| PCT/EP2016/058810 WO2016170014A1 (en) | 2015-04-21 | 2016-04-20 | A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513862A JP2018513862A (ja) | 2018-05-31 |
| JP2018513862A5 true JP2018513862A5 (OSRAM) | 2019-04-25 |
| JP6721606B2 JP6721606B2 (ja) | 2020-07-15 |
Family
ID=53298950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554426A Active JP6721606B2 (ja) | 2015-04-21 | 2016-04-20 | シェーグレン症候群の治療にける使用のための特定のトリフルオロエチルキノリン類似体 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10493074B2 (OSRAM) |
| EP (1) | EP3285772B1 (OSRAM) |
| JP (1) | JP6721606B2 (OSRAM) |
| KR (1) | KR102627370B1 (OSRAM) |
| CN (1) | CN107530344B (OSRAM) |
| AR (1) | AR105552A1 (OSRAM) |
| AU (1) | AU2016251236B2 (OSRAM) |
| BR (1) | BR112017020591B8 (OSRAM) |
| CA (1) | CA2981631C (OSRAM) |
| CL (1) | CL2017002669A1 (OSRAM) |
| CO (1) | CO2017010573A2 (OSRAM) |
| CY (1) | CY1122572T1 (OSRAM) |
| DK (1) | DK3285772T3 (OSRAM) |
| EA (1) | EA032432B1 (OSRAM) |
| ES (1) | ES2763335T3 (OSRAM) |
| GB (1) | GB201506786D0 (OSRAM) |
| HR (1) | HRP20192273T1 (OSRAM) |
| HU (1) | HUE047162T2 (OSRAM) |
| IL (1) | IL254766B (OSRAM) |
| LT (1) | LT3285772T (OSRAM) |
| MX (1) | MX2017013148A (OSRAM) |
| MY (1) | MY192972A (OSRAM) |
| PL (1) | PL3285772T3 (OSRAM) |
| PT (1) | PT3285772T (OSRAM) |
| SG (1) | SG11201707789YA (OSRAM) |
| SI (1) | SI3285772T1 (OSRAM) |
| WO (1) | WO2016170014A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201708856D0 (en) | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2873875T3 (es) * | 2004-05-13 | 2021-11-04 | Icos Corp | Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano |
| DK2137186T3 (en) * | 2007-03-23 | 2016-04-18 | Amgen Inc | Heterocyclic compounds and their uses |
| PT2496567T (pt) * | 2009-11-05 | 2017-11-15 | Rhizen Pharmaceuticals S A | Novos moduladores de quinase benzopiran |
| UA112517C2 (uk) * | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
| JP6030783B2 (ja) * | 2013-06-14 | 2016-11-24 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤 |
-
2015
- 2015-04-21 GB GBGB1506786.1A patent/GB201506786D0/en not_active Ceased
-
2016
- 2016-04-20 EA EA201792318A patent/EA032432B1/ru not_active IP Right Cessation
- 2016-04-20 MY MYPI2017703917A patent/MY192972A/en unknown
- 2016-04-20 PL PL16719356T patent/PL3285772T3/pl unknown
- 2016-04-20 SI SI201630565T patent/SI3285772T1/sl unknown
- 2016-04-20 WO PCT/EP2016/058810 patent/WO2016170014A1/en not_active Ceased
- 2016-04-20 PT PT167193564T patent/PT3285772T/pt unknown
- 2016-04-20 CA CA2981631A patent/CA2981631C/en active Active
- 2016-04-20 MX MX2017013148A patent/MX2017013148A/es active IP Right Grant
- 2016-04-20 ES ES16719356T patent/ES2763335T3/es active Active
- 2016-04-20 AR ARP160101079A patent/AR105552A1/es not_active Application Discontinuation
- 2016-04-20 DK DK16719356.4T patent/DK3285772T3/da active
- 2016-04-20 LT LTEP16719356.4T patent/LT3285772T/lt unknown
- 2016-04-20 SG SG11201707789YA patent/SG11201707789YA/en unknown
- 2016-04-20 EP EP16719356.4A patent/EP3285772B1/en active Active
- 2016-04-20 HR HRP20192273TT patent/HRP20192273T1/hr unknown
- 2016-04-20 BR BR112017020591A patent/BR112017020591B8/pt active IP Right Grant
- 2016-04-20 HU HUE16719356A patent/HUE047162T2/hu unknown
- 2016-04-20 KR KR1020177031275A patent/KR102627370B1/ko active Active
- 2016-04-20 JP JP2017554426A patent/JP6721606B2/ja active Active
- 2016-04-20 CN CN201680022982.1A patent/CN107530344B/zh active Active
- 2016-04-20 US US15/565,866 patent/US10493074B2/en active Active
- 2016-04-20 AU AU2016251236A patent/AU2016251236B2/en not_active Ceased
-
2017
- 2017-09-28 IL IL254766A patent/IL254766B/en active IP Right Grant
- 2017-10-17 CO CONC2017/0010573A patent/CO2017010573A2/es unknown
- 2017-10-20 CL CL2017002669A patent/CL2017002669A1/es unknown
-
2019
- 2019-12-23 CY CY20191101354T patent/CY1122572T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| JP2013520405A5 (OSRAM) | ||
| WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| JP2016163571A5 (OSRAM) | ||
| MX2021002322A (es) | Nuevos metodos. | |
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| JP2016512248A5 (OSRAM) | ||
| HRP20161379T1 (hr) | Inhibitori hepatitis c virusa | |
| JP2012532874A5 (OSRAM) | ||
| RU2018144187A (ru) | Специфический аналог трифторэтилхинолина для применения при лечении apids | |
| JP2015534562A5 (OSRAM) | ||
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| HK1214765A1 (zh) | 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 | |
| HK1211475A1 (en) | Combination therapy | |
| JP2017222722A5 (OSRAM) | ||
| WO2014027975A3 (en) | Novel orally administered pharmaceutical formulations | |
| JP2015512406A5 (OSRAM) | ||
| JP2016147915A5 (OSRAM) | ||
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| JP2014198723A5 (OSRAM) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| WO2015107536A3 (en) | Fixed dose combination comprising linagliptin and metformin hci | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population |